Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinserzin versus daily recombinant human growth hormone in children with Noonan syndrome
ChiCTR2200065823Phase 4Not yet recruiting
- Sponsor
- Shallghai Children's Medical Center
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trametinib and cetirizine in Noonan syndrome (2 arms), sponsored by Shallghai Children's Medical Center. Primary endpoints: Safety assessment and Height. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
trametinibcetirizine
03
Conditions
Noonan syndrome
Beyond the preview
Go deeper on ChiCTR2200065823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065823.